tradmap

MBX Earnings Mbx Biosciences, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$32 -$16 $0 2023 2024 2025
EPS
Net income (annual)
-$87M -$44M $0 2023 2024 2025
Net income
Return on equity (annual)
-24% 10% 45% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$24 -$12 $0 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$37M -$12M $14M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-10% 3% 16% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–12 of 12
Q2 20262026-06-30-1.292026-08-0610-Q
Q1 20262026-03-31-0.502026-05-0710-Q
FY 20252025-12-31-2.382026-03-1210-K
Q3 20252025-09-30-1.932025-11-0610-Q
Q2 20262025-06-30-1.302026-08-0610-Q
Q1 20262025-03-31-0.712026-05-0710-Q
FY 20252024-12-31-5.822026-03-1210-K
Q3 20252024-09-30-15.422025-11-0610-Q
Q2 20252024-06-30-22.932025-08-0710-Q
Q1 20252024-03-31-10.262025-05-1210-Q
FY 20242023-12-31-31.962025-03-1710-K
Q3 20242023-09-30-24.282024-11-0710-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.